Arch Therapeutics, Inc.

Market Cap $799.99K
Debt $NaN
Cash $30.03K
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$12.99M
EBIT	-$4.72M
ROA	-338%
Equity	-$12.56M
Growth Stability	1
PE	-0.06
PB	-0.06
P/S	5.4
Price/Cash	0.04
Net Margins	-10K%
Gross Margins	40%
Op. Margins	-3K%
Sales Growth YoY	133%
Sales Growth QoQ	-3%
Sales CAGR	5%
Equity CAGR	-0%
Earnings Growth YoY	250%

Earnings Growth QoQ	335%
Sales CAGR 5Y	124%
Earnings CAGR 3Y	187%
Sales CAGR 3Y	187%
Market Cap	$799.99K
Revenue	$148.16K
Assets	$1.40M
Cash	$30.03K
Shares Outstanding	4.44M
Working Capital	-12.57M
Current Ratio	0.1
Gross Profit	$58.64K
Shares Growth 3y	-27%
Equity Growth QoQ	15%
Equity Growth YoY	57%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Arch Therapeutics Inc is a development stage biotechnology company. It focuses on developing products which manages surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.

SEC Filings

Direct access to Arch Therapeutics, Inc. (ARTH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-Q Dec 31
- 10-K Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-Q Dec 31
- 10-K Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Arch Therapeutics, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Arch Therapeutics, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Arch Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Arch Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Arch Therapeutics, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	TTM
Net Margins	-	-	-	-	-	-	-54K%	-34K%	-9K%	-10K%
ROA	-	-118%	-120%	-154%	-220%	-250%	-173%	-219%	-258%	-338%
ROE	-	-190%	-350%	-354%	563%	313%	608%	126%	93%	-

Bad Net Margins (-9.7K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	TTM
Debt over FCF	-	-	-0	-	-0	-0.03	-0	-0.65	-	-
Debt over Equity	0.31	0.28	0	-	-0	-0.12	-0	-0.69	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	35%	384%	124%
Earnings YoY growth	-	103%	30%	-38%	-6%	3%	33%	-15%	32%	-
Equity YoY growth	-	105%	-30%	-39%	-159%	86%	-32%	309%	79%	-
FCF YoY growth	-	-	18%	5%	-11%	-4%	18%	-25%	-24%	-